Previous studies have reported that ER-positive breast cancers generally demonstrate lower rates of pathologic complete response (pCR) to neoadjuvant chemotherapy compared with HER2-positive or triple-negative breast cancers [20,21]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.